Guggenheim Downgrades Tenax Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 89.7%

Neg 89.7% Neu 0% Pos 0%

Guggenheim analyst Seamus Fernandez downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral.

Comments

No comments yet. Be the first!